BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17329852)

  • 1. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
    Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
    Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
    Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
    Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure.
    Horiuchi I; Nozawa T; Fujii N; Inoue H; Honda M; Shimizu T; Taguchi M; Hashimoto Y
    Biol Pharm Bull; 2008 May; 31(5):976-80. PubMed ID: 18451529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol.
    Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
    J Pharm Pharm Sci; 2006; 9(1):101-12. PubMed ID: 16849011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT2B7*3 did not affect the pharmacokinetics of R- and S-carvedilol in healthy Japanese.
    Honda M; Toyoda W; Shimizu T; Horiuchi I; Kayano Y; Taguchi M; Nozawa T; Inoue H; Hashimoto Y
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):382-6. PubMed ID: 17965522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
    Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
    Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers.
    Honda M; Ogura Y; Toyoda W; Taguchi M; Nozawa T; Inoue H; Hashimoto Y
    Biol Pharm Bull; 2006 Apr; 29(4):772-8. PubMed ID: 16595916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers.
    Honda M; Nozawa T; Igarashi N; Inoue H; Arakawa R; Ogura Y; Okabe H; Taguchi M; Hashimoto Y
    Biol Pharm Bull; 2005 Aug; 28(8):1476-9. PubMed ID: 16079496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
    Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
    Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
    Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
    J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of carvedilol in patients with congestive heart failure.
    Nikolic VN; Jankovic SM; Velickovic-Radovanović R; Apostolović S; Stanojevic D; Zivanovic S; Stefanovic N; Pesic S; Jevtovic-Stoimenov T; Djuric J; Markovic V; Milovanovic JR
    J Pharm Sci; 2013 Aug; 102(8):2851-8. PubMed ID: 23728853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.
    Graff DW; Williamson KM; Pieper JA; Carson SW; Adams KF; Cascio WE; Patterson JH
    J Clin Pharmacol; 2001 Jan; 41(1):97-106. PubMed ID: 11225566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
    Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
    Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.
    Giessmann T; Modess C; Hecker U; Zschiesche M; Dazert P; Kunert-Keil C; Warzok R; Engel G; Weitschies W; Cascorbi I; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2004 Mar; 75(3):213-22. PubMed ID: 15001973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity.
    Takekuma Y; Takenaka T; Yamazaki K; Ueno K; Sugawara M
    Biol Pharm Bull; 2007 Nov; 30(11):2146-53. PubMed ID: 17978490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
    Luzum JA; Sweet KM; Binkley PF; Schmidlen TJ; Jarvis JP; Christman MF; Sadee W; Kitzmiller JP
    Pharm Res; 2017 Aug; 34(8):1615-1625. PubMed ID: 28181117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats.
    Kim MS; Baek IH
    Eur J Pharm Sci; 2018 Jan; 111():13-19. PubMed ID: 28942006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.
    Tenero DM; Henderson LS; Campanile AM; Baidoo CA; Boyle D
    Am J Cardiol; 2006 Oct; 98(7A):27L-31L. PubMed ID: 17023229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetic-Pharmacodynamic Modeling of Carvedilol to Evaluate the Effect of Cytochrome P450 2D6 Genotype on the Heart Rate Reduction.
    Hwang S; Lee S; Yoon J; Chung JY
    J Korean Med Sci; 2023 Jun; 38(22):e173. PubMed ID: 37272562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.